Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure

Yana Anfinogenova, Elena V. Grakova, Maria Shvedova, Kristina V. Kopieva, Alexander T. Teplyakov, Sergey V. Popov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalHeart Failure Reviews
Volume23
Issue number3
DOIs
Publication statusAccepted/In press - 29 Aug 2017

Fingerprint

Hypoglycemia
Heart Failure
Telemedicine
Hypoglycemic Agents
Pharmaceutical Preparations
Nutritionists
Genetic Testing
Masks
Thyroid Hormones
Catecholamines
Cardiac Arrhythmias
Cause of Death
Diabetes Mellitus
Thrombosis
Chronic Disease
Technology
Safety
Glucose
Drug Therapy
Health

Keywords

  • Chronic heart failure
  • Diabetes
  • Hypoglycemia
  • Hypoglycemia unawareness
  • Interdisciplinary

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. / Anfinogenova, Yana; Grakova, Elena V.; Shvedova, Maria; Kopieva, Kristina V.; Teplyakov, Alexander T.; Popov, Sergey V.

In: Heart Failure Reviews, Vol. 23, No. 3, 29.08.2017, p. 1-17.

Research output: Contribution to journalArticle

Anfinogenova, Yana ; Grakova, Elena V. ; Shvedova, Maria ; Kopieva, Kristina V. ; Teplyakov, Alexander T. ; Popov, Sergey V. / Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. In: Heart Failure Reviews. 2017 ; Vol. 23, No. 3. pp. 1-17.
@article{5bba8bd92cdd4e3bae34937f2fc8328b,
title = "Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure",
abstract = "Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.",
keywords = "Chronic heart failure, Diabetes, Hypoglycemia, Hypoglycemia unawareness, Interdisciplinary",
author = "Yana Anfinogenova and Grakova, {Elena V.} and Maria Shvedova and Kopieva, {Kristina V.} and Teplyakov, {Alexander T.} and Popov, {Sergey V.}",
year = "2017",
month = "8",
day = "29",
doi = "10.1007/s10741-017-9647-y",
language = "English",
volume = "23",
pages = "1--17",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure

AU - Anfinogenova, Yana

AU - Grakova, Elena V.

AU - Shvedova, Maria

AU - Kopieva, Kristina V.

AU - Teplyakov, Alexander T.

AU - Popov, Sergey V.

PY - 2017/8/29

Y1 - 2017/8/29

N2 - Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.

AB - Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.

KW - Chronic heart failure

KW - Diabetes

KW - Hypoglycemia

KW - Hypoglycemia unawareness

KW - Interdisciplinary

UR - http://www.scopus.com/inward/record.url?scp=85028524613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028524613&partnerID=8YFLogxK

U2 - 10.1007/s10741-017-9647-y

DO - 10.1007/s10741-017-9647-y

M3 - Article

VL - 23

SP - 1

EP - 17

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 3

ER -